{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T08:31:03Z","timestamp":1782203463727,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacl.2025.04.203","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T23:23:02Z","timestamp":1746832982000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real life evidence of volanesorsen for familial chylomicronemia syndrome in Colombia"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5942-1035","authenticated-orcid":false,"given":"Alejandro","family":"Rom\u00e1n-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Castellanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6020-6516","authenticated-orcid":false,"given":"Diego","family":"Perdomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Col\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jose","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5546-4206","authenticated-orcid":false,"given":"Carlos O.","family":"Mendivil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnayro","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jacl.2025.04.203_bib0001","article-title":"Brazilian Position Statement for Familial Chylomicronemia Syndrome - 2023","volume":"120","author":"Izar","year":"2023","journal-title":"Arq Bras Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2025.04.203_bib0002","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacl.2021.10.004","article-title":"Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: an expert panel discussion","volume":"15","author":"Santos","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2025.04.203_bib0003","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/17446651.2024.2365787","article-title":"Etiology and emerging treatments for familial chylomicronemia syndrome","volume":"19","author":"Spagnuolo","year":"2024","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.jacl.2025.04.203_bib0004","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4158\/EP-2018-0157","article-title":"Familial chylomicronemia syndrome: a clinical guide for endocrinologists","volume":"24","author":"Falko","year":"2018","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.jacl.2025.04.203_bib0005","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jacl.2018.05.013","article-title":"Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study","volume":"12","author":"Blom","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2025.04.203_bib0006","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jacl.2018.07.013","article-title":"Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society","volume":"12","author":"Ariza","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2025.04.203_bib0007","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s13023-023-02927-8","article-title":"Symptoms and impacts of familial chylomicronemia syndrome: a qualitative study of the patient experience","volume":"18","author":"Williams","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"10.1016\/j.jacl.2025.04.203_bib0008","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14779072.2017.1372193","article-title":"The burden of familial chylomicronemia syndrome from the patients' perspective","volume":"15","author":"Gelrud","year":"2017","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"5","key":"10.1016\/j.jacl.2025.04.203_bib0009","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14779072.2017.1311786","article-title":"The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study","volume":"15","author":"Davidson","year":"2017","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"4","key":"10.1016\/j.jacl.2025.04.203_bib0010","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jacl.2018.04.009","article-title":"The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study","volume":"12","author":"Davidson","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2025.04.203_bib0011","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/CRD.0000000000000468","article-title":"Drug therapy for hypertriglyceridemia and familial chylomicronemia syndrome: focus on volnesorsen","volume":"31","author":"Gesner","year":"2023","journal-title":"Cardiol Rev"},{"issue":"4","key":"10.1016\/j.jacl.2025.04.203_bib0012","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1194\/jlr.M066399","article-title":"Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results","volume":"57","author":"Yang","year":"2016","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.jacl.2025.04.203_bib0013","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11883-017-0697-3","article-title":"ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen","volume":"19","author":"Rocha","year":"2017","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"10.1016\/j.jacl.2025.04.203_bib0014","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13841","article-title":"Volanesorsen to treat severe hypertriglyceridaemia: a pooled analysis of randomized controlled trials","volume":"52","author":"Calcaterra","year":"2022","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"10.1016\/j.jacl.2025.04.203_bib0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12020-022-03025-8","article-title":"Efficacy and safety of the apolipoprotein C-III inhibitor volanesorsen: a systematic evaluation and meta-analysis","volume":"76","author":"Cheng","year":"2022","journal-title":"Endocrine"},{"issue":"12","key":"10.1016\/j.jacl.2025.04.203_bib0016","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","article-title":"Volanesorsen: first global approval","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.jacl.2025.04.203_bib0017","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacl.2025.04.203_bib0018","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/14779072.2018.1487290","article-title":"The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study","volume":"16","author":"Arca","year":"2018","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"10.1016\/j.jacl.2025.04.203_bib0019","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jacl.2023.03.007","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: long-term efficacy and safety data from patients in an open-label extension trial","volume":"17","author":"Witztum","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.04.203_bib0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2023.05.008","article-title":"Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS)","volume":"375","author":"Jones","year":"2023","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.jacl.2025.04.203_bib0021","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.jacl.2025.04.203_bib0022","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11883-020-00836-w","article-title":"Efficacy and safety of volanesorsen (ISIS 304801): the evidence from phase 2 and 3 clinical trials","volume":"22","author":"Fogacci","year":"2020","journal-title":"Curr Atheroscler Rep"},{"issue":"5","key":"10.1016\/j.jacl.2025.04.203_bib0023","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s11154-024-09893-x","article-title":"Inhibitors of apolipoprotein C3, triglyceride levels, and risk of pancreatitis: a systematic review and meta-analysis","volume":"25","author":"Masson","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"issue":"19","key":"10.1016\/j.jacl.2025.04.203_bib0024","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jacl.2025.04.203_bib0025","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425002788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425002788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T11:53:59Z","timestamp":1749210839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425002788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":25,"alternative-id":["S1933287425002788"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.04.203","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real life evidence of volanesorsen for familial chylomicronemia syndrome in Colombia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.04.203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}